Table 2 List of ICD-O-3 codes included in the analysis, number of cases, median age and crude and age-standardized incidence rates of myeloid neoplasms diagnosed during 2002–2013 in Spain.
ICD-O-3 codes | N | Median age (IQR) | CR total | ASRE total | ASRE men | ASRE women | Sex ratio | |
|---|---|---|---|---|---|---|---|---|
MPN | 5872 | 69 (54–78) | 4.68 | 5.14 (5.00; 5.27) | 6.08 (5.86; 6.3) | 4.41 (4.24; 4.58) | 1.38 | |
Chronic myeloid leukemia | 9863, 9875 | 1324 | 62 (46–76) | 1.06 | 1.13 (1.06; 1.19) | 1.45 (1.35; 1.56) | 0.85 (0.78; 0.92) | 1.71 |
Polycythemia vera | 9950 | 1064 | 71 (59–78) | 0.85 | 0.95 (0.89; 1.01) | 1.12 (1.02; 1.21) | 0.82 (0.75; 0.89) | 1.37 |
Primary myelofibrosis | 9961 | 457 | 71 (63–77) | 0.36 | 0.41 (0.38; 0.45) | 0.65 (0.58; 0.72) | 0.23 (0.19; 0.27) | 2.83 |
Essential thrombocythemia | 9962 | 2401 | 68 (53–78) | 1.91 | 2.10 (2.01; 2.18) | 2.14 (2.01; 2.27) | 2.09 (1.98; 2.20) | 1.02 |
Chronic neutrophilic/eosinophilic leukemia | 9963–9964 | 53 | 66 (55–74) | 0.04 | 0.05 (0.03; 0.06) | 0.07 (0.04; 0.09) | 0.03 (0.02; 0.04) | 2.33 |
Mastocytosis | 9740–9742 | 83 | 54 (36–66) | 0.07 | 0.07 (0.05; 0.09) | 0.08 (0.06; 0.10) | 0.06 (0.04; 0.08) | 1.33 |
MPN unclassifiable | 9960 | 490 | 75 (63–81) | 0.39 | 0.43 (0.39; 0.47) | 0.58 (0.51; 0.65) | 0.33 (0.29; 0.38) | 1.76 |
MDS/MPN | 912 | 77 (70–83) | 0.73 | 0.83 (0.78; 0.88) | 1.35 (1.24; 1.46) | 0.47 (0.42; 0.53) | 2.87 | |
Chronic myelomonocytic leukemia | 9945 | 763 | 77 (70–83) | 0.61 | 0.70 (0.65; 0.75) | 1.16 (1.06; 1.26) | 0.38 (0.33; 0.43) | 3.05 |
Juvenile myelomonocytic leukemia | 9846 | 8 | 0 (0–0) | 0.01 | 0.01 (0.00; 0.01) | 0.01 (0.00; 0.01) | 0.00 (0.00; 0.01) | - |
Atypical chronic myeloid leukemia | 9876 | 49 | 73 (59–80) | 0.04 | 0.04 (0.03; 0.06) | 0.07 (0.05; 0.09) | 0.02 (0.01; 0.04) | 3.50 |
MDS/MPN, unclassifiable | 9975 | 92 | 81 (73–86) | 0.07 | 0.08 (0.07; 0.1) | 0.11 (0.08; 0.14) | 0.07 (0.05; 0.09) | 1.57 |
MDS | 5213 | 78 (71–83) | 4.16 | 4.71 (4.59; 4.84) | 6.54 (6.3; 6.79) | 3.47 (3.33; 3.62) | 1.88 | |
MDS with single lineage dysplasia | 9980, 9991 | 731 | 78 (72–83) | 0.58 | 0.66 (0.61; 0.71) | 0.87 (0.78; 0.95) | 0.52 (0.46; 0.57) | 1.67 |
MDS with ring sideroblasts and single lineage dysplasia | 9982 | 471 | 77 (70–82) | 0.38 | 0.42 (0.39; 0.46) | 0.62 (0.54; 0.69) | 0.29 (0.25; 0.33) | 2.14 |
MDS with excess of blasts | 9983 | 912 | 75 (68–80) | 0.73 | 0.82 (0.77; 0.88) | 1.19 (1.09; 1.29) | 0.54 (0.48; 0.60) | 2.20 |
MDS with multilineage dysplasia | 9985 | 782 | 77 (70–82) | 0.62 | 0.70 (0.65; 0.75) | 1.02 (0.92; 1.11) | 0.47 (0.42; 0.53) | 2.17 |
MDS associated with isolated del(5q) | 9986 | 116 | 75 (67–79) | 0.09 | 0.10 (0.09; 0.12) | 0.06 (0.04; 0.08) | 0.14 (0.11; 0.17) | 0.43 |
MDS unclassifiable | 9989 | 2201 | 80 (73–86) | 1.76 | 2.01 (1.92; 2.09) | 2.79 (2.63; 2.96) | 1.51 (1.42; 1.61) | 1.85 |
AML | 4498 | 68 (50–78) | 3.59 | 3.91 (3.79; 4.02) | 4.75 (4.55; 4.94) | 3.28 (3.14; 3.42) | 1.45 | |
AML with recurrent cytogenetic abnormalities | 608 | 49 (35–67) | 0.48 | 0.5 (0.46; 0.54) | 0.55 (0.49; 0.61) | 0.46 (0.41; 0.52) | 1.20 | |
AML with t(8;21)(q22;q22) | 9896 | 115 | 60 (40–73) | 0.09 | 0.10 (0.08; 0.12) | 0.11 (0.08; 0.14) | 0.09 (0.06; 0.11) | 1.22 |
AML with 11q23 abnormalities | 9897 | 17 | 67 (56–77) | 0.01 | 0.01 (0.01; 0.02) | 0.02 (0.01; 0.03) | 0.01 (0.00; 0.02) | 2.00 |
AML with inv(16)(p13;q22) or t(16;16)(p13;q11) | 9871 | 45 | 51 (29–72) | 0.04 | 0.04 (0.03; 0.05) | 0.06 (0.04; 0.08) | 0.02 (0.01; 0.03) | 3.00 |
AML with t(15;17)(q22;q11-12) | 9866 | 431 | 47 (33–63) | 0.34 | 0.35 (0.32; 0.38) | 0.37 (0.32; 0.42) | 0.34 (0.30; 0.39) | 1.09 |
AML with multilineage dysplasia | 9895, 9984 | 494 | 74 (66–80) | 0.39 | 0.44 (0.40; 0.48) | 0.61 (0.54; 0.68) | 0.32 (0.27; 0.36) | 1.91 |
AML and MDS therapy related | 9920, 9987 | 120 | 66 (56–73) | 0.10 | 0.11 (0.09; 0.13) | 0.10 (0.07; 0.13) | 0.12 (0.09; 0.15) | 0.83 |
AML NOC | 2136 | 66 (49–77) | 1.70 | 1.85 (1.77; 1.93) | 2.26 (2.13; 2.40) | 1.53 (1.43; 1.62) | 1.48 | |
AML minimal differentiated | 9872 | 334 | 72 (57–79) | 0.27 | 0.29 (0.26; 0.33) | 0.39 (0.33; 0.45) | 0.23 (0.19; 0.27) | 1.70 |
AML without maturation | 9873 | 431 | 66 (49–76) | 0.34 | 0.37 (0.34; 0.41) | 0.44 (0.38; 0.49) | 0.32 (0.27; 0.36) | 1.38 |
AML with maturation | 9874 | 324 | 61 (46–73) | 0.26 | 0.28 (0.25; 0.31) | 0.30 (0.25; 0.34) | 0.26 (0.22; 0.30) | 1.15 |
Acute myelomonocytic leukemia | 9867 | 355 | 66 (46–77) | 0.28 | 0.31 (0.27; 0.34) | 0.38 (0.33; 0.44) | 0.24 (0.21; 0.28) | 1.58 |
Acute monoblastic and monocytic leukemia | 9891 | 446 | 65 (46–76) | 0.36 | 0.38 (0.35; 0.42) | 0.48 (0.42; 0.54) | 0.31 (0.27; 0.36) | 1.55 |
Acute erythroid leukemia | 9840 | 137 | 70 (56–78) | 0.11 | 0.12 (0.10; 0.14) | 0.17 (0.13; 0.20) | 0.08 (0.06; 0.10) | 2.13 |
Acute megakaryoblastic leukemia | 9910 | 30 | 48 (2–67) | 0.02 | 0.02 (0.02; 0.03) | 0.03 (0.01; 0.04) | 0.02 (0.01; 0.03) | 1.50 |
Acute basophilic leukemia | 9870 | 2 | 80 (77–83) | 0.00 | 0.00 (0.00; 0.00) | 0.00 (0.00; 0.01) | 0.00 (0.00; 0.00) | - |
Acute panmyelosis with myelofibrosis | 9931 | 43 | 71 (64–76) | 0.03 | 0.04 (0.03; 0.05) | 0.05 (0.03; 0.07) | 0.03 (0.02; 0.05) | 1.67 |
Myeloid sarcoma | 9930 | 34 | 66 (41–76) | 0.03 | 0.03 (0.02; 0.04) | 0.03 (0.02; 0.05) | 0.02 (0.01; 0.04) | 1.50 |
AML NOS | 9861 | 1140 | 73 (58–80) | 0.91 | 1.01 (0.95; 1.07) | 1.23 (1.13; 1.33) | 0.85 (0.78; 0.93) | 1.45 |
Acute leukemia of ambiguous lineage | 395 | 75 (60–83) | 0.32 | 0.35 (0.32; 0.39) | 0.41 (0.35; 0.47) | 0.30 (0.26; 0.35) | 1.37 | |
Acute leukemia, NOS | 9801 | 346 | 76 (64–83) | 0.28 | 0.31 (0.28; 0.34) | 0.35 (0.30; 0.41) | 0.28 (0.23; 0.32) | 1.25 |
Biphenotypic acute leukemia | 9805, 9807–9809 | 49 | 57 (37–72) | 0.04 | 0.04 (0.03; 0.05) | 0.06 (0.04; 0.08) | 0.03 (0.01; 0.04) | 2.00 |
Unknown myeloid neoplasms | 9860, 9800, 9965, 9967 | 632 | 81 (73–86) | 0.50 | 0.58 (0.53; 0.62) | 0.79 (0.7; 0.88) | 0.45 (0.40; 0.50) | 1.76 |
Total cases | 17,522 | 73 (60–81) | 13.97 | 15.52 (15.29; 15.75) | 19.92 (19.51; 20.33) | 12.39 (12.12; 12.67) | 1.61 |
